Adaptive Biotechnologies Announces a Collaboration with Sanofi
Credit: Adaptive Biotechnologies
Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announced that it entered into an agreement with Sanofi to utilize Adaptive’s NGS-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to isatuximab. This investigational anti-CD38 monoclonal antibody is in clinical development for the treatment of newly diagnosed, relapsed and/or refractory multiple myeloma (MM).
Through this collaboration, the parties will work together to evaluate the clinical value of monitoring MRD negativity in isatuximab-treated MM patients. Adaptive will be responsible for seeking regulatory approvals for and commercialization of the clonoSEQ Assay in MM for select geographies. Adaptive will receive upfront payments and potential future milestone payments. Financial terms of the agreement were not disclosed.
“Adaptive is thrilled to apply its technology to help determine the depth and duration of response to isatuximab in MM-treated patients,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “We look forward to kicking off our collaboration and applying our validated, highly sensitive and quantitative clonoSEQ Assay to measure MRD status as a clinical endpoint in Sanofi’s clinical trials.”
The use of residual disease assessment to inform drug development has steadily increased in the past few years. Currently, there are three published meta-analyses1,2,3 describing the utility of incorporating a highly sensitive MRD measurement to evaluate a patient’s response to therapy. This collaboration is Adaptive’s fourth collaboration with leading biopharmaceutical companies.
“MRD status is being incorporated as an important clinical endpoint to assess response to therapy in patients with multiple myeloma and other lymphoid malignancies,” said Charles Sang, Adaptive’s Senior Vice President, Diagnostics. “We are excited to work with Sanofi on its late-stage MM trials to help demonstrate the clinical utility of achieving MRD negativity in isatuximab-treated patients.”
About Minimal/Measurable Residual Disease
Minimal/measurable residual disease (MRD) refers to cancer cells that remain in the body of a person with lymphoid cancer after treatment. These cells can be present at levels undetectable by traditional morphologic, microscopic examination of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ Assay, are needed for reliable detection of MRD at levels below the limits of traditional assessment.